Multipark Coordinator & Chair of Board Professor Susanne Iwarsson

1. Multipark Coordinator & Chair of Board Professor Susanne Iwarsson Assistant Coordinator & Deputy Chair of Board Associate Professor Oskar Hansson

2. Multipark Strategic research area Advertised, applied for and evaluated by means of traditional grant mechanisms Transferred to the university in the annual government budget proposition Faculty funding – management decided by the university & faculty

3. Multipark 2010 - 2014 110 MSEK funding for 5 years (10, 16, 28, 28 and 28 MSEK) 3% Gothenburg University 5% Vice-chancellor, Lund University

4. Multipark strategy

5. MISSION

6. Goal & Aims • The principal goal is to create a program that improves body function and structure, as well as activity and participation, among PD patients. In order to reach this goal, we aim to: • Perform the first transplantation trial using stem cells • Perform clinical trials using gene-transfer based therapy • Perform clinical trials using small molecule based neuro-protective agents • Implement accurate tools for estimation of the outcome of these trials (e.g. wet biomarkers, improved rating-scales and bio-imaging) • Test the effects of evidence-based clinical interventions

7. Multipark focus

8. Executive group Working groups Board

9. Board Chair: Susanne Iwarsson* Deputy Chair: Oskar Hansson* Faculty management representative: Ingemar Carlstedt (?) Anders Björklund Elisabet Londos Cecilia Lundberg* Per Odin* Roger Olsson* Jens Schouenborg PhD student representative: Hjalmar Bjartmarz PhD student representative: Zuzanna Kurowska * Executive Group

10. Education & InnovationDirector of Studies: Associate professor Helena JernströmInnovation Group:Thomas Laurell, Roger Olsson, Tadeusz Wieloch

11. Infrastructure

12. Done so far • Grant manager, information officer, research & clinical administrators • Director of Studies, 30% • Infrastructure investments (two major equipment, plus technical & statistics resources) • Travel grants • Six 3rd year post-docs

13. Done so far • Adjunct professor Roger Olsson & co-worker = Drug Discovery Node • Professorship in Chemical Biology and Drug Discovery; one applicant under review • Health Sciences Node established (postdoc, guest researchers, PhD students, facilities) • Professor Jan Lexell • Professor Gunnar Gouras & co-worker • Three junior group leaders with start-up packages(T. Björklund, L. Roybon, M. Svanberg)

14. Done so far • Clinical Sciences Node coming • Visiting professor Paola Piccini • Clinical Researcher, R. Smith – visiting Hammersmith Hospital, London • Professorship in Clinical Neuroscience ratified by Faculty Board • Four 50% clinical research positions under review (16 applicants)

16. Economic Results

17. 2012 2013 2014 2015 2016 2017 Management+joint activities Infrastructure (evaluation 2013) FoAss Start-up Packages FoAss Graduate School Profs Start-up Packages Prof PhD students Clinical Researchers Postdocs Other activities (i.e. innovation) TOTAL costs (MSEK) Available (MSEK) 28.5 11.75 9.19 8.81 1.5 15.40 17.97 18.34

21. 2012 and on • Communication & active engagement • Infrastructure and innovation • Experimental Sciences Node – current standing & future development • Health Sciences, Clinical & Drug Discovery Nodes – development intensified • Strategic development, aiming for 2015 and onwards